🇺🇸 Empa in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Catheterisation Cardiac — 1 report (12.5%)
2. Coronary Angioplasty — 1 report (12.5%)
3. Coronary Arterial Stent Insertion — 1 report (12.5%)
4. Febrile Neutropenia — 1 report (12.5%)
5. Injection Site Warmth — 1 report (12.5%)
6. Pain In Extremity — 1 report (12.5%)
7. Sepsis — 1 report (12.5%)
8. Vascular Pain — 1 report (12.5%)

Source database →

Frequently asked questions

Is Empa approved in United States?

Empa does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Empa in United States?

Beni-Suef University is the originator. The local marketing authorisation holder may differ — check the official source linked above.